English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background New drugs must be deemed safe and effective by the Food and Drug Administration (FDA) before they are made available to the public. The FDA can also withdraw drugs from the market if unexpected adverse effects are detected in postmarketing surveillance after initial approval. The U.S. General Accounting Office (GAO) reviewed ten prescription drugs withdrawn from the market during the period of January 1997 and December 2000 and found that 8 out of the 10 drugs were withdrawn due to adverse events occurring predominantly in women. Women were at greater risk for valvular heart disease for the appetite suppressants fenfluramine and dexfenfluramine, and Torsades de Pointes for the

Sex and the basic scientist: is it time to embrace Title IX?